An official website of the United States government
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Entyvio (Vedolizumab) [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2016 Dec.
| Drug/Comparator | Strength | Dosage Form | Price | Recommended Dosea | Drug Cost in Year 1 | Average Drug Cost Subsequent Years |
|---|---|---|---|---|---|---|
| Vedolizumab (Entyvio) | 300 mg | Vial for IV infusion | $3,290.00b | 300 mg at weeks 0, 2, and 6, followed by every 8 weeks thereafter | $26,320 | $21,458 |
| TNF Alpha Inhibitors | ||||||
| Adalimumab (Humira) | 40 mg | Pen for SC injection | 740.36 | 160 mg week 0, 80 mg week 2, 40 mg week 4 and every 2 weeks thereafter | $22,211 | $19,315 |
| Infliximab (Remicade) | 100 mg | Vial for IV infusion | $987.56 | 5 mg/kg at weeks 0, 2, and 6, then every 8 weeks thereafter May be increased to 10 mg/kg every 8 weeks in patients who have lost response | $31,602 to $46,415 | $25,765 to $,45,088 |
| Infliximab (Inflectra) | 100 mg | Vial for IV infusion | $$525.00c | 5 mg/kg at weeks 0, 2, and 6, then every 8 weeks thereafter May be increased to 10 mg/kg every 8 weeks in patients who have lost response | $16,800 to $24,675 | $13,697 to $23,970 |
IV = intravenous; ODB = Ontario Drug Benefit; SC = subcutaneous; TNF alpha = tumour necrosis factor alpha.
Note: All prices are from the ODB Formulary Exceptional Access Program (July 2016) unless otherwise indicated.
Manufacturer’s submitted and current market price.
ODB Formulary list price.
From: SUMMARY
Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence (CC BY-NC-ND), a copy of which is available at http://creativecommons.org/licenses/by-nc-nd/4.0/
Your browsing activity is empty.
Activity recording is turned off.
See more...
